Patents by Inventor Jose Corvalan
Jose Corvalan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10118968Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: December 29, 2009Date of Patent: November 6, 2018Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20160152713Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: August 6, 2015Publication date: June 2, 2016Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 9096672Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: March 2, 2009Date of Patent: August 4, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9085624Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: November 10, 2008Date of Patent: July 21, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9073998Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: March 2, 2009Date of Patent: July 7, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9062113Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: November 10, 2008Date of Patent: June 23, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20130024956Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20120225014Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicants: Pfizer Inc., Amgen Fremont Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 7736644Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 25, 2004Date of Patent: June 15, 2010Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20100111979Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: December 29, 2009Publication date: May 6, 2010Applicant: AMGEN FREMONT INC.Inventors: RICHARD WEBER, XIAO FENG, ORIT FOORD, LARRY GREEN, JEAN M. GUDAS, BRUCE KEYT, YING LIU, PALANISWAMI RATHANASWAMI, ROBERT RAYA, XIAO DONG YANG, JOSE CORVALAN, IAN FOLTZ, XIAO-CHI JIA, JASPAL S. KANG, CHADWICK T. KING, SCOTT L. KLAKAMP, QIAOJUAN JANE SU
-
Publication number: 20100098694Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: October 9, 2009Publication date: April 22, 2010Applicants: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 7628986Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 25, 2004Date of Patent: December 8, 2009Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 7626012Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: September 22, 2008Date of Patent: December 1, 2009Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 7618633Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: September 25, 2007Date of Patent: November 17, 2009Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20090240038Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: March 2, 2009Publication date: September 24, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 7563442Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: August 26, 2005Date of Patent: July 21, 2009Assignees: Abgenix, Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20090175887Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: March 2, 2009Publication date: July 9, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20090169563Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: September 25, 2007Publication date: July 2, 2009Applicants: Abgenix, Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20090155282Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: November 10, 2008Publication date: June 18, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20090156790Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: November 10, 2008Publication date: June 18, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su